Chronic inflammation in musculoskeletal pathology
Osteoarthritis represents a complex musculoskeletal disorder characterized by degeneration of articular cartilage, joint pain, and progressive functional impairment. It mainly affects weight-bearing joints such as the knees and hips, where chronic mechanical stress contributes to structural deterioration and symptomatic disability. Patients typically present with joint pain, swelling, morning stiffness, and progressive restriction of movement, which together lead to a deterioration in quality of life. Conventional conservative strategies are largely palliative and do not reverse the underlying degenerative process, underscoring the need for approaches that can influence the biological mechanisms sustaining chronic joint pathology.
From a pathophysiological perspective, osteoarthritis is described as an active disease process with an imbalance between repair and destruction of joint tissues. Poor intrinsic healing capacity is related to limited vascularization and the absence of direct access to bone marrow progenitor cells within articular cartilage and adjacent structures. This environment favors persistence of low-grade inflammation and progressive matrix degradation rather than effective regeneration. The chronicity of symptoms and structural changes reflects this failure of endogenous reparative mechanisms to counteract ongoing catabolic stimuli.
Risk factors such as age, heredity, obesity, and local biomechanical alterations including joint injury, laxity, or malalignment further amplify the burden of chronic inflammation in osteoarthritis. These factors increase mechanical load and microtrauma, which in turn sustain inflammatory signaling within the joint. Clinically, this is expressed as persistent pain, stiffness, and functional limitation, often progressing despite standard non-regenerative interventions. The expected rise in osteoarthritis prevalence with population aging and increasing obesity highlights the clinical relevance of strategies that can modulate inflammatory and degenerative cascades rather than only alleviating symptoms.
Current non-surgical treatments for osteoarthritis include physical therapy, weight loss, lifestyle modification, pharmacologic therapies, steroid injections, and intra-articular hyaluronic acid injections. These approaches aim to relieve pain, slow functional decline, and improve biomechanics, but none have been shown to reverse or repair the degenerative nature of the disease. In this context, chronic inflammation remains only partially controlled, and structural joint damage continues to progress in many patients. This therapeutic gap has driven interest in regenerative strategies, particularly those based on autologous mesenchymal stromal cells, which may influence both inflammatory activity and tissue repair processes in musculoskeletal pathology.
Immunomodulatory role of stromal cells
Autologous Regenerative Therapy is described as an innovative medical discipline that aims to regenerate injured tissues or stimulate their repair using the patient’s own cells, particularly autologous mesenchymal stromal cells (MSCs), in a single medical procedure. Mesenchymal cells are characterized by their ability to differentiate according to signals from the surrounding environment and specific growth factors, making them suitable elements to support healing in lesions involving different tissues. In the orthopedic field, adipose-derived stem cells (ADSCs), located predominantly in the stromal vascular fraction of adipose tissue, are frequently used because of their intrinsic capacity to contribute to the regeneration of cartilage, tendons, and bone.
Adipose tissue is recognized as a promising source of multipotent mesenchymal stromal cells similar to those found in bone marrow. The stromal vascular fraction contains interrelated cell populations including adipocyte progenitors, pericytes, endothelial progenitor cells, and transit-amplifying cells, which together provide a rich cellular milieu for regenerative applications. Among these, adipose-derived stromal/stem cells exhibit the capacity to differentiate into adipogenic, osteogenic, and chondrogenic lineages, as demonstrated in vitro for cells obtained from micro-fragmented adipose tissue harvested with specialized cannulas. This multilineage potential supports their use in musculoskeletal conditions where cartilage and subchondral bone are affected.
Beyond differentiation, adipose-derived stromal cells display immunomodulatory, antifibrotic, antiapoptotic, and pro-angiogenic properties. These cells secrete bioactive molecules that stimulate angiogenesis and contribute to modulation of local inflammatory responses. Stromal cells and pericytes derived from adipose tissue have been described as secreting a wide variety of factors with immunomodulatory and neovascularization properties, which are considered central to their regenerative role. Such properties are relevant in osteoarthritis, where chronic low-grade inflammation and impaired microvascular support contribute to tissue degeneration.
The immunomodulatory characteristics of adipose-derived stromal cells have been associated with clinical effects in different settings, including improved skin trophism, accelerated closure of complex wounds or ulcers, and enhancement of skin appearance after radiotherapy damage. These observations support the concept that the therapeutic impact of autologous adipose-derived cell preparations extends beyond simple structural replacement, involving active modulation of the tissue microenvironment. In musculoskeletal applications, intra-articular administration of adipose-derived stromal cell–rich preparations is therefore positioned not only as a structural regenerative strategy but also as a means to influence inflammatory pathways that sustain osteoarthritic joint damage.
Paracrine signaling and cytokine profiles
The regenerative effect of adipose tissue–based therapies is attributed to the presence of adipose-derived stem cells, cytokines, growth factors, pre-adipocytes, and mature adipocytes within the graft. Adipose-derived stem cells display the ability to secrete bioactive molecules that stimulate angiogenesis and exert antifibrotic, antiapoptotic, and immunomodulatory actions. This secretory activity underpins a paracrine mechanism through which autologous regenerative therapy can influence the local joint environment in osteoarthritis, even when direct differentiation into cartilage or bone cells is not the predominant effect.
Stromal cells and pericytes contained in adipose-derived preparations are described as secreting a wide variety of factors with anti-fibrotic, anti-apoptotic, immunomodulatory, and neo-vascularization properties. These paracrine mediators are implicated in clinical observations such as improved skin trophism, accelerated wound closure, and enhanced tissue quality after radiotherapy. By analogy, in the osteoarthritic joint, similar paracrine signaling is expected to support microvascular function, reduce fibrotic remodeling, and modulate inflammatory cell activity, thereby contributing to symptomatic improvement and functional gains.
The harvesting and processing strategies used in autologous regenerative therapy are designed to preserve the viability and functional capacity of stromal vascular fraction cells. Micro-fragmented adipose tissue obtained with small-port cannulas, without substantial mechanical or chemical manipulation, has been shown to contain viable and proliferative cells, with cell viability comparable to that of tissue processed by enzymatic digestion. This minimally manipulated tissue naturally contains stromal vascular fraction cells and mesenchymal stem cells, and is considered a promising source for regenerative treatments. Preservation of cell viability and structural integrity supports sustained paracrine activity after intra-articular injection.
Adipose-derived mesenchymal stromal cells isolated from lipoaspirate harvested with SEFFI and micro-SEFFI cannulas have been shown to form colony-forming units and to differentiate towards adipogenic, osteogenic, and chondrogenic lineages, confirming their stemness potential. The capacity of these cells to proliferate and maintain functional properties after harvesting suggests that their paracrine signaling profile can be preserved in clinical preparations. In the context of osteoarthritis, such paracrine signaling is aligned with the therapeutic goal of modulating inflammation and supporting repair, rather than solely providing mechanical cushioning within the joint.
Balance between inflammation and repair
Osteoarthritis is explicitly described as an active disease process characterized by an imbalance between repair and destruction of joint tissues. Poor intrinsic healing power and limited regenerative capacity are linked to poor vascularization and the lack of direct access to bone marrow progenitor cells in the affected joint structures. This imbalance favors catabolic pathways and chronic inflammation, leading to progressive cartilage loss and joint dysfunction. Therapeutic strategies that introduce exogenous regenerative cells aim to shift this balance toward repair by providing both cellular and paracrine support.
Autologous Regenerative Therapy utilizes the patient’s own mesenchymal stromal cells in a single procedure to stimulate tissue repair. Adipose-derived stem cells, particularly those within the stromal vascular fraction, are frequently used in orthopedics because of their capacity to contribute to regeneration of cartilage, tendons, and bone. Their ability to differentiate in response to environmental signals and growth factors, combined with their secretion of bioactive molecules with immunomodulatory and antiapoptotic properties, positions them as active modulators of the repair–destruction balance in osteoarthritic joints.
The SEFFI-based technique for harvesting micro-fragmented adipose tissue is designed to obtain a highly fluid preparation of adipose clusters during the harvesting step, without the need for further manipulation. This approach aims to preserve stemness and cell viability, as mechanical manipulation has been associated with reduced viability and growth potential. A comparative study confirmed that tissue harvested with guided microcannulas with small side-port holes, without substantial manipulation, contains viable and proliferative cells and is therefore considered a promising tissue for regenerative therapy. By maintaining a robust population of functional stromal cells, such preparations are better positioned to support reparative processes in the joint.
In clinical application to hip and knee osteoarthritis, intra-articular injection of fat micrograft rich in stromal vascular fraction cells has been associated with improvements in range of motion and reductions in stiffness and pain over follow-up periods of months. These functional gains suggest a shift in the local joint environment toward improved tissue performance, which is consistent with enhanced repair and modulation of inflammatory activity. While the study cohort is limited and lacks a control group, the observed outcomes, particularly in younger patients with lower osteoarthritis grades, support the concept that autologous regenerative therapy can influence the dynamic balance between inflammation-driven degeneration and reparative responses in musculoskeletal pathology.
Clinical observations and anti-inflammatory effects
An observational retrospective study evaluated intra-articular injection of autologous fat micrograft obtained with the SEFFI device in 250 patients with initial-stage degenerative hip or knee osteoarthritis. The procedure involved harvesting donor adipose tissue, isolating the stromal vascular fraction–containing micro-fragmented fat, and injecting it intra-articularly, all within approximately 60 to 70 minutes. The donor site postoperative course was uneventful apart from minimal discomfort, edema, and ecchymosis, and no major complications such as infection were observed. At the injected site, patients experienced swelling and low-grade pain for 3–7 days, with no reported adverse events or infections, and the autologous material was well tolerated.
Clinically, patients demonstrated an average increase in joint range of motion of about 10 degrees at three months after treatment, accompanied by reduced stiffness as reported during clinical assessment. Pain, measured using a Visual Analogue Scale, began to decrease at three months and reached more pronounced reductions at six months for the knee and between six and twelve months for the hip. These temporal patterns suggest that the clinical benefits of autologous regenerative therapy, including potential anti-inflammatory effects, develop progressively over several months rather than immediately after injection.
Patient-reported outcomes further support a favorable clinical profile. In this cohort, 85% of patients reported being satisfied one year after treatment and indicated they would undergo the procedure again, citing considerable improvement in pain and quality of life. SF-12 questionnaire results reflected good physical and mental health component scores, with patients generally reporting minimal limitations in moderate activities, no significant interference of pain with normal work, and a perception of very good general health. These findings are consistent with a clinically meaningful reduction in symptom burden and functional impairment.
The low complication rate and favorable tolerance profile observed in this and other reports have led authors to consider mesenchymal stem cell–based treatments as a good option to improve quality of life in patients with mild or moderate osteoarthritis, and in selected severe cases where patients decline surgical treatment. Although results are variable and not yet predictable, and the available data are limited by retrospective design and absence of control groups, the combination of pain reduction, improved joint performance, and high patient satisfaction suggests that autologous regenerative therapy exerts clinically relevant effects that may include modulation of inflammatory processes within the joint.
Potential for disease modification
Conventional conservative treatments for osteoarthritis, including physical therapy, pharmacologic agents, steroid injections, and intra-articular hyaluronic acid, are primarily palliative and do not reverse or repair the degenerative nature of the disease. In contrast, stem cell–based approaches are emerging as potential strategies for tissue repair and regeneration in orthopedics, with applications in avascular bone necrosis, osteochondral defects, pseudoarthrosis, and traumatic cartilage defects. Within this context, autologous adipose-derived stromal cell therapies are being investigated for their capacity to influence structural and symptomatic aspects of osteoarthritis.
The observational experience with intra-articular injection of fat micrograft in hip and knee osteoarthritis indicates that this minimally invasive procedure can replace or considerably delay the need for major joint replacement surgery in a subset of patients, due to its impact on quality of life and associated costs. Over a five-year follow-up, only a small proportion of treated patients proceeded to joint replacement, and these were older individuals with more advanced disease. While these data do not establish definitive structural modification, they suggest that autologous regenerative therapy may alter the clinical trajectory of osteoarthritis in some cases.
The biological rationale for potential disease modification rests on the combined differentiation and paracrine capacities of adipose-derived stromal cells. These cells can differentiate into chondrocytes and osteogenic lineages and secrete bioactive molecules that stimulate angiogenesis and exert antifibrotic, antiapoptotic, and immunomodulatory effects. Stromal cells and pericytes from adipose tissue secrete factors that promote neovascularization and modulate inflammatory responses, which may contribute to improved tissue quality and function over time. By addressing both structural and inflammatory components of osteoarthritis, autologous regenerative therapy has a mechanistic basis for influencing disease progression.
Nonetheless, current evidence from the described cohort is limited by retrospective design, absence of a control group, and relatively short to intermediate follow-up. Authors emphasize the need for expanded studies including control groups and additional variables such as limb length discrepancy, systemic comorbidities, axis defects, and prior trauma to refine indications and better characterize outcomes. Further research with rigorous methodology is required to clarify the extent to which autologous adipose-derived stromal cell therapies can be considered disease-modifying in osteoarthritis, beyond their demonstrated capacity to improve symptoms and function in selected patient populations.
Sources (Bibliography)
- Trentani P, Meredi E, Zarantonello P, Gennai A. Role of Autologous Micro-Fragmented Adipose Tissue in Osteoarthritis Treatment. J Pers Med, 2024.
- Gennai A, Bovani B, Colli M, Melfa F, Piccolo D, Russo R, Roda B, Zattoni A, Reschiglian P, Zia S. Comparison of Harvesting and Processing Technique for Adipose Tissue Graft: Evaluation of Cell Viability. Int J Regener Med, 2021.
- Rossi M, Alviano F, Ricci F, et al. In vitro multilineage potential and immunomodulatory properties of adipose derived stromal/stem cells obtained from nanofat lipoaspirates. CellR4 Repair Replace Regen Reprogram, 2016.
- Characterization of Tissue and Stromal Cell for Facial Aging Treatment, 2020.